Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02350777 · ClinicalTrials.gov registry record · Phase 2
T-cell Depleted Hematopoietic Stem Cell Boosts Without Conditioning for Poor Marrow Graft Function Following Allogeneic Hematopoietic Stem Cell Transplantation
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT02350777: Clinical Trial Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02350777 is a Phase 2 study that was terminated before completion, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 4 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02350777, a Phase 2 study, was terminated before completion, sponsored by Memorial Sloan Kettering Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to see if giving the patient stem cells their original donor (boost) after removing the T cells (T cell depleted- TCD boost) without further chemotherapy. The investigators want to see if this can improve bone marrow function. This would also improve the patients white blood counts, red blood counts and platelets. This may make the patients chances of improving and surviving better. The investigators will also be looking at the short term side effects and risks of the TCD boost.
Primary Outcome
will be documented by CBC checks every 2 weeks. Response will be defined by stable blood counts (ANC\>1000, Hb\>8 with absolute reticulocyte count\>20x10\^9/L ,and Plt\>50,000) without support of blood product transfusions and/or growth factors.
Interventions
- PROCEDURE Donor peripheral blood progenitor cells: stimulation, harvesting, isolation and T-cell depletion
- DEVICE CliniMACS Cell Selection System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2015-01-21 |
| Est. Completion | 2017-10-25 |
| Phase | Phase 2 |
Why NCT02350777 stopped before completion
NCT02350777 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Donor peripheral blood progenitor cells: stimulation, harvesting, isolation and T-cell depletion is the first listed.
NCT02350777 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02350777 about?
NCT02350777 is a clinical study titled "T-cell Depleted Hematopoietic Stem Cell Boosts Without Conditioning for Poor Marrow Graft Function Following Allogeneic Hematopoietic Stem Cell Transplantation". The purpose of this study is to see if giving the patient stem cells their original donor (boost) after removing the T cells (T cell depleted- TCD boost) without further chemotherapy. The investigators want to see if this can improve bone marrow function. This would also improve the patients white b...
What is the current status of trial NCT02350777?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2015-01-21. Estimated completion is 2017-10-25.
What interventions are being tested in trial NCT02350777?
The interventions under investigation include: Donor peripheral blood progenitor cells: stimulation, harvesting, isolation and T-cell depletion (PROCEDURE), CliniMACS Cell Selection System (DEVICE).
Who is sponsoring clinical trial NCT02350777?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02350777's enrollment target sits among peer trials
4 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI